

**AMENDMENT TO THE SPECIFICATION:**

Please amend the specification as follows. On page 8, line 25 to page 9, line 4, please amend the paragraph as follows:

Thus, the “5-HT<sub>2B</sub> receptor antagonistic compound having a selective binding affinity to the 5-HT<sub>2B</sub> receptor (hereinafter abbreviated to 5-HT<sub>2B</sub> selective antagonistic compound)” includes specifically those selective against  $\alpha_1$ , M<sub>1</sub> and D<sub>2</sub> receptors, preferably against  $\alpha_1$ , M<sub>1</sub>, D<sub>2</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors, more preferably against  $\alpha_1$ , M<sub>1</sub>, D<sub>2</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors.